SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Alerce Investment Management, L.P.

CIK 0001844002 · 676 N. MICHIGAN AVENUE, SUITE 4000, CHICAGO, IL, 60611 · (312) 448-5500

Reported Value
$62M
Q3 2024
Positions
5
Filings on Record
17
2019–present window
Filed
Nov 13, 2024
original filing

Summary

Alerce Investment Management, L.P. reported $62M in U.S.-listed holdings across 5 positions for Q3 2024.

The portfolio is heavily concentrated: ANNX alone accounts for 70.4% of reported value.

Compared with Q2 2024, the fund opened 1 new position and exited 1.

Portfolio Metrics

Turnover
+10.2%
vs prior filed quarter
Largest Position
+70.4%
Annexon
New / Exited
1 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $254MQ4 ’20Q1 ’21: $226MQ2 ’21: $184MQ3 ’21: $146MQ3 ’21Q4 ’21: $98MQ1 ’22: $59MQ2 ’22: $54MQ2 ’22Q3 ’22: $104MQ4 ’22: $87MQ1 ’23: $76MQ1 ’23Q2 ’23: $77MQ3 ’23: $59MQ4 ’23: $75MQ4 ’23Q1 ’24: $95MQ2 ’24: $51MQ3 ’24: $62MQ3 ’24Q4 ’24: $57Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 90.5%ADR: 9.5%
  • Common Stock · 90.5% · $56M
  • ADR · 9.5% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AMWLAMERICAN WELL CORPNEW+523.8K523.8K+$5M$5M
AMERICAN WELL CORPSOLD OUT10.48M0$3M$0
WHWKAADI BIOSCIENCE INCTRIMMED1.63M659$2M$1,358
VRNAVERONA PHARMA PLCHELD7.1K205.9K+$3M$6M
ANNXANNEXON INCHELD+07.41M+$8M$44M
AKBAAKEBIA THERAPEUTICS INCHELD+05.75M+$2M$8M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

5 positions
#IssuerClass% PortfolioValueShares
1ANNXANNEXON INChistory →COM70.35%$44M7.41M
2AKBAAKEBIA THERAPEUTICS INChistory →COM12.17%$8M5.75M
3VRNAVERONA PHARMA PLChistory →SPONSORED ADS9.50%$6M205.9K
4AMWLAMERICAN WELL CORPhistory →COM CL A NEW7.97%$5M523.8K
5WHWKAADI BIOSCIENCE INCCOM0.00%$1,358659

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$57M5Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$62M5Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$51M5Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$95M5May 9, 202413F-HRchanges · EDGAR ↗
Q4 2023$75M5Feb 9, 202413F-HRchanges · EDGAR ↗
Q3 2023$59M6Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$77M6Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$76M6May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$87M6Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$104M7Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$54M7Aug 4, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M7May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$98M7Feb 9, 202213F-HRchanges · EDGAR ↗
Q3 2021$146M7Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$184M7Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$226M7May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$254M7Feb 11, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.